Abel de la Rosa
No más puestos en curso
Fortuna: 860 $ al 31/05/2024
Perfil
Abel de la Rosa worked as a Director at Celtaxsys, Inc. He was also a Vice President-Product Development at Visible Genetics, Inc. from 2002 to 2002.
Additionally, he held the position of Senior VP-Business Development & Scientific Affair at Pharmasset, Inc. from 2011 to 2012.
Dr. de la Rosa completed his undergraduate degree at the University of California San Diego.
He also completed his graduate and doctorate degrees at the University of Miami.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 25/04/2024 | 4 000 ( 0.01% ) | 860 $ | 31/05/2024 |
Antiguos cargos conocidos de Abel de la Rosa.
| Empresas | Cargo | Fin |
|---|---|---|
Visible Genetics, Inc.
 Visible Genetics, Inc. Medical SpecialtiesHealth Technology Visible Genetics, Inc. manufactures and markets automated DNA sequencing systems and diagnostic kits. The company develops genotyping technology that employs DNA sequencing that enables the analysis in the clinical diagnostic laboratory of individual genetic variations. It was founded in 1993 and is headquartered in Toronto, Canada | Corporate Officer/Principal | 01/12/2002 |
Celtaxsys, Inc.
 Celtaxsys, Inc. Pharmaceuticals: MajorHealth Technology Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded by William P. Reddick in 2005 and is headquartered in Atlanta, GA. | Director/Miembro de la Junta | - |
Pharmasset, Inc.
 Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Director Técnico/Científico/I+D | 02/10/2012 |
Formación de Abel de la Rosa.
| University of California San Diego | Undergraduate Degree |
| University of Miami | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 3 |
|---|---|
Pharmasset, Inc.
Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ. | Health Technology |
Visible Genetics, Inc.
Visible Genetics, Inc. Medical SpecialtiesHealth Technology Visible Genetics, Inc. manufactures and markets automated DNA sequencing systems and diagnostic kits. The company develops genotyping technology that employs DNA sequencing that enables the analysis in the clinical diagnostic laboratory of individual genetic variations. It was founded in 1993 and is headquartered in Toronto, Canada | Health Technology |
Celtaxsys, Inc.
Celtaxsys, Inc. Pharmaceuticals: MajorHealth Technology Celtaxsys, Inc. operates as a clinical-stage drug discovery and development company that focuses on novel therapeutics to treat patients suffering from inflammatory diseases. It offers CTX-4430, a small-molecule drug that targets the enzyme Leukotriene A4 hydrolase in immune cells for the treatment of cystic fibrosis and moderately severe acne diseases. The company was founded by William P. Reddick in 2005 and is headquartered in Atlanta, GA. | Health Technology |
- Bolsa de valores
- Insiders
- Abel de la Rosa
